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Abstract
Patient-reported outcomes (PROs) such as quality of life and work productivity are important for measuring patient’s experience. We
assessed PROs during and after treatment of hepatitis C virus (HCV) patients.
Data were obtained from a phase 3 open label study of sofosbuvir and ribavirin (SOF + RBV) with and without interferon (IFN).
Patients completed 4 PRO assessment instruments (SF-36, Functional Assessment of Chronic Illness Therapy—Fatigue, Chronic
Liver Disease Questionnaire— HCV, Work Productivity and Activity—Specific Health Problem) before, during, and after
treatment.
A total of 533 patients with chronic HCV were enrolled; 28.9% treatment-naïve, 23.1% cirrhotic, 219 received IFN + SOF + RBV
and 314 received IFN-free SOF + RBV. At baseline, there were no differences in PROs between the IFN-free and IFN-containing
treatment arms (all P>0.05). During treatment, patients receiving IFN + SOF + RBV had a substantial impairment in their PROs (up to
24.4% by treatment week 12, up to 8.3% at week 4 post-treatment). The PRO decrements seen in the SOF + RBV arm were
smaller in magnitude (up to7.1% by treatment week 12), and all returned to baseline or improved by post-treatment week 4. By 12
weeks after treatment cessation, patients who achieved sustained viral response-12 showed some improvement of PRO scores
regardless of the regimen (up to +7.1%, P<0.0001) or previous treatment experience. In multivariate analysis, the use of IFN was
independently associated with lower PROs.
IFN-based regimens have a profoundly negative impact to PROs. By contrast, the impact of RBV on these PROs is relatively
modest. Achieving HCV cure is associated with improvement of most of the PRO scores.
Abbreviations: CLDQ-HCV = Chronic Liver Disease Questionnaire—Hepatitis C Virus, DAA = direct-acting antiviral agent,
FACIT-F= Functional Assessment of Chronic Illness Therapy—Fatigue, FS = Fatigue Scale, HCV = hepatitis C virus, HRQL = health-
related quality of life, IFN = interferon, PRO = patient-reported outcome, RBV = ribavirin, SF-36 = Short Form-36, SOF = sofosbuvir,
SVR = sustained viral response, WPAI:SHP = Work Productivity and Activity—Specific Health Problem.
Keywords: direct-acting antivirals, fatigue, work productivity
1. Introduction
The new direct-acting antiviral agents (DAAs) for treatment of
hepatitis C virus (HCV) have revolutionized HCV treatment with
high sustained viral response (SVR) rates and superior patient-
reported outcomes (PROs).[1–12] Although new interferon (IFN)-
free and ribavirin (RBV)-free regimens are currently being
developed, both IFN and RBV remain a part of certain
regimens.[1–4]
Previous studies have shown that treatment-naïve HCV
patients treated with RBV and IFN experience a significant
PRO impairment.[13,14] In particular, the use of IFN causes
substantial side effects, including debilitating ones such as
severe depression, which, in turn, affect patients’ ability to
sustain treatment long enough to obtain a cure whether through
medical discontinuation or through patients’ nonadherence.
The use of RBV also has been shown to decrease PROs during
treatment. However, the PRO data in patients who are
retreated after having experienced another course of treatment
have not been reported. Therefore, the aim of this study was to
evaluate PROs during treatment with and without the use of
IFN in patients who participated in a prior study of an IFN-
containing or an IFN-free DAA-based regimen and has not
achieved SVR.
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Data were obtained from a phase 3 multicenter open label study
investigating the use sofosbuvir (SOF); the study protocol GS-US-
334-0109, ClinicalTrials.gov identifier NCT01625338. The
target population was patients with all genotypes chronic
HCV infection who participated in another study of an SOF-
based regimen and did not achieve SVR after receiving active
treatment or a placebo; in this study, patients who received a
placebo were considered to be treatment-naive. The original
intent of this trial was to provide the best opportunity to achieve
SVR to participants of prior clinical trials who had experienced a
treatment failure or happened to be assigned to a placebo arm.
For this study, patients were assigned to receive either IFN + SOF
+ RBV for 12 weeks or SOF + RBV for 12 or 24 weeks; no
randomization or blinding was used. Exclusion criteria were
coinfection with HBV or human immunodeficiency virus,
pregnancy, history of clinical hepatic decompensation, or the
use of immunosuppressants, or other substances as specified in
the study report.
We used the medical history collected at screening for the study
participants to identify patients with a history of psychiatric
disorders, sleep disorders, fatigue or asthenia, and type 2 diabetes
or hyperglycemia. Adverse events related to treatment, as
confirmed by the study investigators, were grouped into 9
disorder types depending on the organ system involved: blood
and lymphatic, gastrointestinal, musculoskeletal and connective
tissue, nervous, psychiatric, skin and subcutaneous tissue,
fatigue, flu-like symptoms, and other disorders, as described
previously.[11,12]
2.1. Assessment of PROs
In this study, PROs were collected as secondary endpoints using
standard instruments.[15–19] All instruments were self-adminis-
tered by patients prior to initiation of any study-related activities
at baseline (day 1) visit, treatment week 12, and at post-treatment
weeks 4, 12, and 24 while blinded to their most recent HCVRNA
levels.
A Short Form-36 (SF-36) questionnaire is a generic instrument,
which has been extensively validated in a variety of populations.
It is used to calculate 8 health-related quality of life (HRQL)
domains: Physical Functioning, Role Physical, Bodily Pain,
General Health, Vitality, Social Functioning, Role Emotional,
andMental Health. The 2 summary scores, which are designed to
be linear combinations of these 8 domains, summarize physical
and mental health. The 2011 US population norms were used for
normalization.[15]
The Functional Assessment of Chronic Illness Therapy—
Fatigue (FACIT-F) is another widely usedHRQL instrument with
a fatigue-specific component. It includes a core which consists of
the Physical, Emotional, Social, and Functional Well-Being
domains and the Fatigue Scale (FS).[16] All domains add up to the
total FACIT-F score.
The Chronic Liver Disease Questionnaire—HCV (CLDQ-
HCV) is a disease-specific instrument that targets HRQL
impairment in patients with chronic HCV infection. It includes
4 HRQL domains: Activity/Energy, Emotional, Worry, and
Systemic, which are averaged to the total CLDQ-HCV score.[17]
The Work Productivity and Activity—Specific Health Problem
(WPAI:SHP) is a different PRO instrument, which is widely used
to quantify impairment in patients’ work productivity and daily
activities that, as patient believes, is a consequence of a specific
health problem (HCV infection, for the purpose of this study). It
has 2 domains. The work productivity impairment domain is a
sum of impairment in work productivity due to missed work
hours (absenteeism) and due to decreased productivity while
working (presenteeism); this domain is assessed in employed
patients only. The other domain is activity impairment domain,
which is impairment in daily activities other than work; it is
assessed regardless of employment.[18] Unlike other instruments,
all domains of WPAI:SHP are supposed to be inversely related to
health status; that is, a greater impairment indicates worse health,
and vice versa.
We also calculated SF-6D health utility scores, which are
preference-based measures for health necessary for calculation of
quality-adjusted years of life in economic analyses; an SF-36
instrument and a nonparametric Bayesian model were used as
previously described.[19]
2.2. Statistical analysis
The treatment regimens were grouped into IFN-free (SOF + RBV)
and IFN-containing (IFN+ SOF+RBV) regardless of the duration.
For all patients, all individual PRO domains, summary PROs, and
health utility scores were calculated at each study time point and
were further used for calculation of changes (decrements or
improvements) in PROs and utilities from patients’ own baseline
levels, thus,making patients their own controls. For the purpose of
comparison betweenmultiple PROs domains, these domains were
transformed from their original scales to a universal 0 to 100 scale
with greater scores representing better well-being.
All demographic and clinical parameters, as well as PROs and
changes in those, were summarized as mean± standard deviation
or frequency (percentage) in the treatment arms separately, and
were compared between the study arms using Wilcoxon rank
sum nonparametric test (continuous parameters) or Pearson chi-
squared test (categorical parameters). The decrements/improve-
ments in PROs at the study time points from patients’ own
baseline were tested for significance using Wilcoxon sign-rank
test for matched pairs; a P value of 0.05 was used as a threshold
for significance. In a separate round of analysis, independent
predictors of summary PROs and SF-6D utility scores were
assessed at the study time points separately using multiple linear
regressions with stepwise selection of predictors; only predictors
with P<0.05 were left in the final regression models. In the
regression analyses, demographic and clinical variables together
with the treatment regimen were tested as potential predictors.
All analyses were run in SAS 9.3 (SAS Institute, Cary, NC).
The study was separately approved by each site’s Institutional
Review Board. Participants signed an informed consent before
being enrolled in the trial.
3. Results
There were 533 patients in this study (Table 1). Of those, 219
patients received 12 weeks of IFN + SOF + RBV, 114 patients
received 12 weeks of SOF + RBV, and 200 patients received 24
weeks of SOF + RBV.
The demographic and clinical parameters of patients receiving
IFN-containing versus IFN-free treatment are listed in Table 1.
Patients receiving an IFN-containing regimen were older, more
likely African-American, less cirrhotic and treatment-naïve, had
predominantly HCV genotype 1, and reported having less
depression or mood disorders at screening (all P<0.05, Table 1).
On the other hand, patients assigned to an IFN-free SOF + RBV
regimen were predominantly HCV genotype 3 or 2 (Table 1).
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During treatment, significantly more patients in the IFN +
SOF + RBV arm experienced at least 1 treatment-related side
effect when compared to the SOF + RBV arm: 89.0% versus
69.7% (P<0.0001). The most frequently reported side effects
were fatigue (52.0% vs 30.2%, P<0.0001), depression and
other psychiatric issues (45.2% vs 30.6%, P=0.0006), and
joint or muscle soreness (39.3% vs 13.1%, P<0.0001)
(Table 2). The overall rate of SVR was higher in the IFN +
SOF + RBV arm: 82.6% versus 75.5% in SOF + RBV (P=
0.048). That included SVR-12 of 79.85% in HCV genotype 1
patients treated with IFN + SOF + RBV, and 90.5% in IFN +
RBV + SOF arm versus 69.8% in SOF + RBV arm in HCV
genotype 3 patients (P=0.0003).
3.1. PROs during treatment with and without interferon
At baseline, despite some difference in demographic and clinical
presentation, there were no difference in PROs between the 2
treatment arms (all P>0.05) (Supplementary Table 1, http://
links.lww.com/MD/B564).
After 4 weeks of treatment with IFN + SOF + RBV, the PRO
scores were found to be significantly lower than patients’ own
baseline scores (Supplementary Fig. 1, http://links.lww.com/MD/
B564). The negative impact of treatment was found to be most
apparent in the domains of patients’ Work Productivity (the
greatest average decrease of 18.1 on a universal 0–100 scale),
Role Physical of SF-36 (average 16.0), Activity/Energy of
CLDQ-HCV (15.9), Activity of WPAI:SHP (15.5), Physical
Well-Being of FACIT-F (15.3), and FS of FACIT-F (13.8) (all
P<0.0001). The average decrement across 26 studied PROs at
that time point was 9.7 points.
These significant decreases in scores continued throughout
treatment with IFN + RBV + SOF (Fig. 1A). Specifically, at 12
weeks, the decrements were up to24.4 points from baseline; the
largest decrements were again observed inWork Productivity and
a number of physical functioning-related domains including Role
Physical of SF-36, Activity of WPAI:SHP, Physical Well-Being
and FS of FACIT-F, and Activity/Energy of CLDQ-HCV (all P<
0.0001). The average decrement across 26 PROs was 12.8
points, and the only 2 PRO domains in which no statistically
significant decrement was found were the Worry domain of
CLDQ-HCV and the Emotional Well-Being domain of FACIT-F
(Fig. 1A).
The PRO scores in the IFN + RBV + SOF arm remained low
until 4 weeks post-treatment, predominantly in the same areas of
impaired Work Productivity (average 8.3), Role Physical
(5.3), Role Emotional (7.9), Activity (6.2), and Social
Functioning (5.7) (all P<0.002; the average across PROs3.3)
(Supplementary Fig. 2, http://links.lww.com/MD/B564). Despite
this, by post-treatment week 12 in patients with SVR, no PRO
remained lower than the baseline level, and 14 out of 26 PRO
domains improved relative to baseline (by up to +8.0, and by +4.2
on average; all P<0.05) (Fig. 1B). Additionally, by week 24 after
treatment discontinuation, all but 4 average PRO scores (Physical
Functioning, Bodily Pain, Social Functioning of SF-36, and
Absenteeism of WPAI:SHP) were significantly above their
baseline levels (all P<0.05).
In contrast to the IFN-containing regimen, the on-treatment
PRO decrements in patients receiving an SOF + RBV-based
treatment were smaller in magnitude (Fig. 2). In particular, the
average PRO decrement by treatment week 4 was 2.0, with the
greatest decrements observed in Social Functioning of SF-36
(4.4), Physical Well-Being of FACIT-F (4.0), Role Emotional
of SF-36 (3.8), and Presenteeism of WPAI:SHP (3.5) (all P<
0.005) (Supplementary Fig. 1, http://links.lww.com/MD/B564).
Similarly, the decrements observed by treatment week 12 were
also substantially smaller in comparison to those seen in the IFN-
containing arm: up to7.1 points in Social Functioning of SF-36
and 2.9 points across all studied PROs (Fig. 1A).
Furthermore, in patients who received an IFN-free SOF + RBV
regimen, all PROs returned to baseline levels or started to
improve by post-treatment week 4 (improvements up to +4.1
in the Worry domain of CLDQ-HCV, average improvement
across 7 improved PROs +2.1; all P<0.05); no residual PRO
decrement relative to baseline was observed at that time point
Table 1
Baseline demographics and clinical presentation of the study
cohort.





or 24 wk P
N 219 314
Age, y 53.4±10.0 52.3±8.4 0.0152
Male gender 159 (72.6%) 210 (66.9%) 0.16
Caucasian 187 (85.4%) 289 (92.0%) 0.0145
African-American 20 (9.1%) 6 (1.9%) 0.0001
Asian 8 (3.6%) 8 (2.5%) 0.46
Enrolled in the United States 114 (52.0%) 156 (49.7%) 0.59
Employed 137 (69.5%) 150 (58.1%) 0.0125
Cirrhosis 36 (16.4%) 87 (27.7%) 0.0024
Treatment-naïve 15 (6.8%) 139 (44.3%) <0.0001
ALT > 1.5  ULN 110 (50.2%) 184 (58.6%) 0.06
HCV RNA > 6 log 10/mL 183 (83.6%) 240 (76.4%) 0.0454
HCV genotype 1 134 (61.2%) 2 (0.6%) <0.0001
HCV genotype 2 8 (3.7%) 72 (23.0%) <0.0001
HCV genotype 3 74 (33.8%) 232 (74.1%) <0.0001
HCV genotype 4–6 3 (1.4%) 7 (2.2%) 0.47
Hemoglobin, g/dL 14.9±1.3 14.7±1.3 0.11
BMI 28.1±4.4 27.5±4.9 0.11
Baseline history of
Type 2 diabetes 21 (9.6%) 31 (9.9%) 0.91
Anxiety or panic disorders 23 (10.5%) 46 (14.6%) 0.16
Depression or mood disorders 43 (19.6%) 91 (29.0%) 0.0144
Clinically overt fatigue 26 (11.9%) 50 (15.9%) 0.19
Insomnia or sleep disorders 33 (15.1%) 57 (18.1%) 0.35
ALT = alanine aminotransferase, BMI = body mass index, HCV = hepatitis C virus, IFN = interferon,
RBV = ribavirin, SOF = sofosbuvir, ULN = upper limit of the norm.
Table 2
Treatment-related adverse events.





or 24 wk P
Blood or lymphatic system disorders 26 (11.9%) 24 (7.6%) 0.10
Fatigue or asthenia 114 (52.0%) 95 (30.2%) <0.0001
Flu-like symptoms 80 (36.5%) 10 (3.2%) <0.0001
Gastrointestinal system disorders 83 (37.9%) 75 (23.9%) 0.0005
Musculo-skeletal system disorders 86 (39.3%) 41 (13.1%) <0.0001
Nervous system disorders 99 (45.2%) 69 (22.0%) <0.0001
Psychiatric disorders 99 (45.2%) 96 (30.6%) 0.0006
Skin and subcutaneous
tissue disorders
79 (36.1%) 75 (23.9%) 0.0023
Other disorders 131 (59.8%) 87 (27.7%) <0.0001
No treatment-related adverse events 24 (11.0%) 95 (30.2%) <0.0001
IFN = interferon, RBV = ribavirin, SOF = sofosbuvir.
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(Supplementary Fig. 2, http://links.lww.com/MD/B564). By 12
weeks after treatment cessation, in patients with SVR-12, all but
6 PRO scores significantly improved in patients treated with SOF
+ RBV by up to +7.1 points (+4.2 on average; all P<0.03); note
that these improvements are now similar to those observed in the
IFN-containing arm (all P>0.05) (Fig. 1B), and a similar
observation was made at post-treatment week 24 as well.
In multivariate analysis, after adjustment for demographic and
clinical predictors of PROs, which were similar to those reported
previously[8–12,20–23] and included site location, history of
psychiatric disorders, fatigue, cirrhosis, the use of IFN in addition
to SOF + RBV was independently associated with a greater
impairment in PROs during and soon after treatment discontinu-
ation (Table 3). In particular, the magnitude of association (beta)
ranged from8.1 to22.2 at treatment week 12 (all P<0.0001)
and from4.6 to11.9 at post-treatmentweek4 (allP<0.02). By
post-treatment week 12, the Physical Component Summary of SF-
36, the CLDQ-HCV score, and Work Productivity Impairment
score were still associated with treatment received: from 4.5 to
5.6 points for the use of IFN in comparison to the referenceSOF+
RBV regimen (all P<0.05).
3.2. Subgroup analysis: PROs in treatment-experienced
patients treated with IFN
In a separate round of analysis, we tested the hypothesis that the
effect of IFN on PROs may be less pronounced in treatment-
experienced patients who have already been treated with IFN.
For that purpose, we used the subgroup of treatment-experienced
patients currently treated with IFN + SOF + RBV, and compared
baseline PROs and treatment-emergent changes in PROs
between those who had received an IFN-containing regimen
before and those who had received an IFN-free regimen with or
without RBV.
As shown in Supplementary Table 2, http://links.lww.com/
MD/B564 most of the baseline PROs in patients with history of
Figure 1. Average changes in PROs from baseline to (A) treatment week 12 (all P<0.05 between regimens except for FACIT-F: emotional well-being and FACIT-F
social well-being), and (B) post-treatment week 12 (in patients with SVR-12 only; all P>0.05 between regimens). All PROs were transformed to a universal 0 to 100
scale. FACIT-F = Functional Assessment of Chronic Illness Therapy—Fatigue, PRO = patient-reported outcome, SVR = sustained viral response.
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IFN treatment were significantly higher when compared to
baseline PROs in patients who were being retreated after an IFN-
free regimen. These PROs included 4 domains of SF-36 (Role
Physical, General Health, Social Functioning, and Role Emo-
tional), all but one domains of FACIT-F, all domains of CLDQ-
HCV, Activity Impairment of WPAI:SHP, and the SF-6D health
utility score (P<0.05); nearly all of these PROs remained higher
during treatment with IFN in this study. However, no difference
Figure 2. Summary PROs during and after treatment with IFN + RBV + SOF and IFN-free RBV + SOF. AI= activity impairment, FS= Fatigue Scale, IFN= interferon,
MCS = Mental Summary Score, PCS = Physical Summary Score, PRO = patient-reported outcome, RBV = ribavirin, SOF = sofosbuvir, WI = work productivity
impairment. All P<0.05 between SOF+RBV and IFN+SOF+RBV treatment arms at treatment weeks 4 and 12.
Table 3
Independent association of the use of an IFN-containing treatment regimen with PROs during and soon after treatment cessation
(adjusted for age, gender, location, BMI, history of psychiatric disorders, fatigue, and treatment history).
PRO (range) Time point Beta Std. Err. P
SF-36: physical component (25–60) Treatment week 12 4.45 0.86 <0.0001
Post-treatment week 4 No association
SF-36: mental component (15–62) Treatment week 12 4.90 1.02 <0.0001
Post-treatment week 4 No association
FACIT-F: fatigue scale (0–52) Treatment week 12 8.23 1.15 <0.0001
Post-treatment week 4 2.62 1.00 0.0091
FACIT-F: total (0–160) Treatment week 12 18.33 2.70 <0.0001
Post-treatment week 4 8.42 2.76 0.0024
CLDQ-HCV (1–7) Treatment week 12 0.637 0.11 <0.0001
Post-treatment week 4 0.276 0.10 0.0073
WPAI:SHP: work productivity impairment (1–0) Treatment week 12 0.222 0.04 <0.0001
Post-treatment week 4 0.069 0.03 0.0166
WPAI:SHP: activity impairment (1–0) Treatment week 12 0.189 0.03 <0.0001
Post-treatment week 4 0.119 0.03 <0.0001
SF-6D health utility (0.20–1.00) Treatment week 12 0.064 0.01 <0.0001
Post-treatment week 4 0.043 0.01 0.0017
Reference regimen: SOF + RBV.
BMI = body mass index, CLDQ-HCV = Chronic Liver Disease Questionnaire—Hepatitis C Virus, FACIT-F = Functional Assessment of Chronic Illness Therapy—Fatigue, IFN = interferon, PRO = patient-reported
outcome, RBV = ribavirin, SF-36 = Short Form-36, SOF = sofosbuvir, WPAI:SHP = Work Productivity and Activity—Specific Health Problem.
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in treatment-emergent changes in PROs with reference to
patients’ own baseline levels was found between patients treated
with IFN after having failed an IFN-free versus IFN-containing
regimen neither in univariate nor in multivariate analysis (all
P>0.05).
4. Discussion
The purpose of this study was to investigate the impact of
alternative hepatitis C treatment regimens on PROs. In this study,
we have found that patients who were treated with a regimen
containing IFN experienced a substantial decrease in their PRO
scores during and even shortly after treatment. According to the
multivariate analysis, the use of IFN was also found to be an
independent predictor of substantial PRO impairment, and that
association was observed up to 12 weeks after treatment
discontinuation. Although PROs were also impacted by IFN-
free regimens that contained RBV, the magnitude of such impact
is much smaller. These data are consistent with previously
published PRO data.[2–10,21–23]
Across both IFN-free and IFN-containing treatment arms,
PRO domains that were most affected by the treatment were the
domains primarily associated with daily functioning and physical
activity. Thus, it is imperative for healthcare practitioners to
assist patients in dealing with these areas by identifying strategies
patients can pursue to stay active and social.
A number of previous studies of the use of IFN for treatment of
chronic HCV infection have shown the negative effect of IFN on
PROs.[13,14] In this study, we have shown that the impact of IFN-
containing and IFN-free RBV-containing regimens on PROs of
patients who are retreated is similar to those who have never been
treated or have been treated with and IFN-free regimen only. In
fact, experience with previous IFN-based treatment does not
seem to predispose patients for better or worse experience during
another course of treatment. Although HCV patients who were
treatment-experienced with IFN had higher baseline PRO scores,
most of these were likely due to previously applied strict
treatment eligibility criteria.
Amajor limitation of this study is related to the original clinical
trial design, which lacks both randomization and blinding. We,
however, believe that the bias caused by this could be adequately
accounted for by multivariate analysis.
In conclusion, treatment-experienced patients who were
retreated with an IFN-containing regimen experienced signifi-
cantly more impairment of their PROs in comparison to patients
who were treated with an IFN-free regimen regardless of
duration. However, it is important to note that, albeit accom-
panied by an unfavorable patients’ well-being profile, the IFN-
containing regimen was still associated with a higher chance of
SVR, especially in patients with HCV genotype 3. These 2
outcomes represent a trade-off that patients who have failed a
DAA-based regimen may face, although the use of IFN,
hopefully, will be revisited once new DAAs come to market
and provide this cohort of patients with more treatment options.
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